A Multi-centre, Prospective, Noninterventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Oct 2023 Results of pooled post hoc analysis from SURE programme: Canada, Denmark/Sweden, France, Germany, Italy, the Netherlands, Switzerland, Spain and the UK psafety of once-weekly (OW) semaglutide prescribed to adults with type 2 diabetes (T2D) in routine clinical practice presented at the 59th Annual Meeting of the European Association for the Study of Diabetes.
18 Jun 2021 Status changed from active, no longer recruiting to completed.
04 Sep 2020 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com